Related Experiment Video
Updated: Jun 10, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Long term exposure to norharman exacerbates 6-hydroxydopamine-induced parkinsonism: possible involvement of L-type
Hashem Haghdoost-Yazdi1, Sedighe-Sadat Hosseini, Ayda Faraji
1Department of Physiology and Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Bahonar St., Qazvin 3419759811, Iran. hhaghdoost@yahoo.com
Abstract:
beta-Carbolines (BCs) are considered as endogenous neurotoxins that may contribute to the pathogenesis of Parkinson's disease (PD). However, several lines of evidences show that these compounds have neuroprotective effect. This study was designed to assess effect of long term exposure to norharman, a BC compound which in mammalian brain occurs at high levels in the substantia nigra, on the progress of parkinsonism induced by 6-hydroxydopamine (6-OHDA). Animals were daily treated by norharman at doses 100, 200 and 1000microg/kg (i.p.) just before to four weeks after the intrastriatal injection of 6-OHDA. Statistical analysis of apomorphine-induced rotation tests demonstrates that treatment by norharman at doses 200 and 1000microg/kg for four weeks exacerbates significantly behavioral symptoms of the parkinsonism. To explore mechanisms by which norharman affects nigral dopaminergic cells, we studied the role of L-type Ca2+ channels. For this purpose, animals were daily treated with either L-type Ca2+ channel blocker of nifedipine at doses 2 and 5mg/kg (i.p.) or nifedipine together with norharman before to four weeks after the 6-OHDA injection. While treatment with nifedipine improved behavioral symptoms of the parkinsonism, treatment with both nifedipine and norharman had no affect on these symptoms. This data indicates that long term exposure to BCs promote nigral dopaminergic cell death possibly through L-type Ca2+ channels.
Related Concept Videos
Parkinson Disease l: Introduction
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Drugs Affecting Neurotransmitter Synthesis
Parkinson's Disease: Overview
Neural Regulation

